Skip to main content

Table 4 Commonly recommended adjuvant chemotherapy regimens

From: Progress in adjuvant chemotherapy for breast cancer: an overview

Recurrence risk category and definition

Recommended regimens: ER-positive, HER2-negative

Recommended regimens: ER/PR-negative, HER2-negative

Recommended regimens: HER2-positive

Very low risk

• Node-Neg, T1a

No chemotherapy

No chemotherapy

No chemotherapy

Low risk

• Node-Neg, T1b

Consider second generation chemotherapy regimen if RS is high

Consider second generation chemotherapy regimen

Consider weekly paclitaxel + H

• Node-Neg, T1c,

Second generation chemotherapy regimen if RS is high (or consider if intermediate)

Second generation chemotherapy regimen

Weekly paclitaxel + H or TCH

Moderate risk

• Node-Neg, T2

Second or third generation chemotherapy regimen if RS intermediate-high

Third generation chemotherapy regimen

AC-T + H or TCH +/− P

High risk

• 1+ Pos Nodes or T3

Third generation chemotherapy regimen if RS intermediate-high (or 4+ positive nodes irrespective of RS)

Third generation chemotherapy regimen

AC-T + H or TCH+/−P

  1. TCH, Docetaxel, carboplatin, trastuzumab; T, Paclitaxel; AC, Doxorubicin, cyclophosphamide; H, Trastuzumab; P, Pertuzumab; Neg, Negative; Pos, Positive; RS, Recurrence score.